Akebia Therapeutics, Inc. Share Price
NASDAQ: AKBA | Micro CapAkebia Therapeutics, Inc. Stock Performance
Open $0.86 | Prev. Close $1.28 | Circuit Range N/A |
Day Range $0.86 - $1.01 | Year Range $0.82 - $3.79 | Volume 2,54,492 |
Average Traded $0.93 |
Akebia Therapeutics, Inc. Share Price Today
As of 9 August 2026, Akebia Therapeutics, Inc.'s share price is $0.95. The stock opened at $0.86, compared to its previous close of $1.28. During today's trading session, Akebia Therapeutics, Inc.'s share price traded between $0.86 and $1.01, with an average price of $0.93. Over the past 52 weeks, the stock has recorded a high of $3.79 and a low of $0.82. In terms of performance, Akebia Therapeutics, Inc.'s share price has declined by 28.01% over the last six months and is down 69.78% on a year-on-year basis.
Akebia Therapeutics, Inc. Share Price Chart
Akebia Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $244.38M | PE Ratio (TTM) -47.52 | Dividend Yield N/A |
EPS (TTM) $-0.02 | Revenue (TTM) $236.20M | Return On Equity (TTM) -16.39% |
Profit Margin -2.26% | Debt to Equity 5.00 | Quarterly Earnings Growth YoY N/A |
Akebia Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Akebia Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.32 | $1.28 | -3.02% |
Jul 2026 | $1.16 | $1.32 | +17.78% |
Jun 2026 | $1.02 | $1.13 | +9.76% |
May 2026 | $1.40 | $1.02 | -25.99% |
Apr 2026 | $1.41 | $1.39 | -0.36% |
Mar 2026 | $1.28 | $1.39 | +5.30% |
Feb 2026 | $1.39 | $1.32 | -6.38% |
Jan 2026 | $1.60 | $1.41 | -12.15% |
Dec 2025 | $1.59 | $1.60 | +1.58% |
Nov 2025 | $2.19 | $1.58 | -28.34% |
Oct 2025 | $2.72 | $2.21 | -19.53% |
Sep 2025 | $3.09 | $2.74 | -12.88% |
AKBA Share Price FAQs
What is Akebia Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Akebia Therapeutics, Inc. stock?
What is AKBA's market capitalisation today?
What is AKBA's net income for the last quarter?
What is the 5 year returns of AKBA?
What is the high & low stock price of AKBA today?
Can I buy AKBA shares in India?